Literature DB >> 30181661

Eliminating MRD - FDA approval of blinatumomab for B-ALL in complete remission.

Talal Hilal1, Vinay Prasad2,3,4.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 30181661     DOI： 10.1038/s41571-018-0087-y

Source DB:  PubMed          Journal:  Nat Rev Clin Oncol        ISSN： 1759-4774            Impact factor:   66.675


× No keyword cloud information.
  4 in total

1.  Randomized Phase II Study of First-Line Cladribine With Concurrent or Delayed Rituximab in Patients With Hairy Cell Leukemia.

Authors:  Dai Chihara; Evgeny Arons; Maryalice Stetler-Stevenson; Constance M Yuan; Hao-Wei Wang; Hong Zhou; Mark Raffeld; Liqiang Xi; Seth M Steinberg; Julie Feurtado; Lacey James; Wyndham Wilson; Raul C Braylan; Katherine R Calvo; Irina Maric; Alina Dulau-Florea; Robert J Kreitman
Journal:  J Clin Oncol       Date:  2020-02-28       Impact factor: 44.544

Review 2.  Challenges and strategies for next-generation bispecific antibody-based antitumor therapeutics.

Authors:  Heliang Li; Phei Er Saw; Erwei Song
Journal:  Cell Mol Immunol       Date:  2020-04-20       Impact factor: 11.530

Review 3.  Strategies for Manipulating T Cells in Cancer Immunotherapy.

Authors:  Hyang-Mi Lee
Journal:  Biomol Ther (Seoul)       Date:  2022-03-10       Impact factor: 4.231

Review 4.  Clinical Value of Measurable Residual Disease in Acute Lymphoblastic Leukemia.

Authors:  Kyaw Hein; Nicholas Short; Elias Jabbour; Musa Yilmaz
Journal:  Blood Lymphat Cancer       Date:  2022-03-19
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.